Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.
Presenting results from the … Read more
by Mark L. Fuerst
Most people with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and the majority have not had genetic testing.
In a recent article in the ASCO Educational Book, Melissa Frey, MD, MS, … Read more
by Cedars-Sinai
New Studies Led by Cedars-Sinai Investigators Help Pinpoint Genetic Risk Factors Tied to Increased Risk of Ovarian Cancer and Suggest How to Better Identify Women Most At Risk
Image on left: Simon Gayther, PhD, professor of Biomedical Sciences, … Read more
by Karen Blum
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,
by Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
by Mike Bassett
— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more
by Erin Hunter
Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.
A new study shows that access to clinician
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
For … Read more
by Alison Kanski
NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more
by Ariana Pelosci
Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.
Patients with advanced solid tumors who have ATM gene alterations
by Charles Bankhead
— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk
The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more
by Caren Begun
Tennis legend Chris Evert—known for her 18-time grand slam success in the sport—has made recent headlines after revealing an early-stage ovarian cancer diagnosis and speaking out to help others by sharing her personal experience.
According to the … Read more
by M. Alexander Otto, MMS, PA
Despite unequivocal recommendations for universal germline BRCA testing in women with ovarian cancer, an analysis of a large commercial insurance database between 2008 and 2018 found that only about one third (33.9%) of such … Read more
by Cedars-Sinai
Findings Hold Potential for Predicting Many Years in Advance Which Women With the BRCA-1 Mutation Will Develop Disease
Newswise — Los Angeles (December 28, 2021). –Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S., … Read more
by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
By Krista Conger
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Women newly diagnosed with breast or ovarian cancer who are also … Read more
A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more
Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more
Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1… Read more
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
